Chicago Capital LLC Increases Stake in DexCom, Inc. (NASDAQ:DXCM)

Chicago Capital LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 75.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 885,532 shares of the medical device company's stock after purchasing an additional 379,586 shares during the period. DexCom comprises 1.7% of Chicago Capital LLC's investment portfolio, making the stock its 24th biggest position. Chicago Capital LLC owned about 0.23% of DexCom worth $60,473,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Forvis Mazars Wealth Advisors LLC grew its holdings in shares of DexCom by 0.7% during the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after buying an additional 118 shares in the last quarter. Principal Securities Inc. grew its stake in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock valued at $316,000 after acquiring an additional 135 shares in the last quarter. Larson Financial Group LLC raised its holdings in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the last quarter. Nia Impact Advisors LLC lifted its stake in DexCom by 1.4% in the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after purchasing an additional 140 shares in the last quarter. Finally, Level Four Advisory Services LLC lifted its stake in DexCom by 1.1% in the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock worth $1,026,000 after purchasing an additional 150 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Stock Down 0.4%

Shares of NASDAQ DXCM traded down $0.30 during midday trading on Wednesday, hitting $81.53. 760,278 shares of the company's stock were exchanged, compared to its average volume of 3,911,057. The firm's fifty day simple moving average is $79.25 and its 200-day simple moving average is $79.38. The company has a market cap of $31.97 billion, a PE ratio of 60.88, a P/E/G ratio of 1.77 and a beta of 1.46. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.27. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.32 EPS. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, Director Nicholas Augustinos sold 2,618 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $81.69, for a total transaction of $213,864.42. Following the transaction, the director now directly owns 37,083 shares of the company's stock, valued at approximately $3,029,310.27. This trade represents a 6.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the transaction, the executive vice president now owns 95,602 shares in the company, valued at approximately $8,057,336.56. This represents a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,474 shares of company stock worth $1,887,026 in the last ninety days. 0.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on DXCM shares. Canaccord Genuity Group upped their price target on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. The Goldman Sachs Group initiated coverage on DexCom in a report on Friday, May 30th. They set a "buy" rating and a $104.00 price target for the company. Citigroup reissued a "buy" rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Finally, Piper Sandler decreased their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.